{"pii": "S0304383524003136", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S0304383524003136-ga1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0304383524003136/ga1/DOWNSAMPLED/image/jpeg/b093b2c20236a3dd0b8bfaf3a083be9d/ga1.jpg"}, {"#name": "file-basename", "_": "ga1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "ga1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "110500"}, {"#name": "pixel-height", "_": "200"}, {"#name": "pixel-width", "_": "355"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S0304383524003136-ga1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0304383524003136/ga1/THUMBNAIL/image/gif/e496c4a916a78fc74dc4c907abbefe92/ga1.sml"}, {"#name": "file-basename", "_": "ga1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "ga1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "81657"}, {"#name": "pixel-height", "_": "123"}, {"#name": "pixel-width", "_": "219"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S0304383524003136-ga1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0304383524003136/HIGHRES/image/jpeg/dbf8ac36d5eb3195ab8141a89c6568cb/ga1_lrg.jpg"}, {"#name": "file-basename", "_": "ga1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "ga1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "340463"}, {"#name": "pixel-height", "_": "886"}, {"#name": "pixel-width", "_": "1574"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"lang": "en", "id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "_": "Sleep disorders are prevalent and debilitating symptoms in primary brain tumor patients, notably those receiving radiation therapy. Nevertheless, the relationship between sleep disorders, melatonin - a circadian rhythm regulatory hormone, and gliomas is underexplored. Melatonin exhibits various biological functions, one of them being anti-tumor activity. In the context of gliomas, often overexpressing EGFR, the humanized monoclonal antibody Nimotuzumab targets this marker. Our research discovered that variations in circadian rhythm significantly influence tumor growth in mice through impacting melatonin secretion. Harnessing proteogenomic, we identified that melatonin could inhibit the phosphorylation of EGFR and its downstream effectors, key elements in angiogenesis and tumor progression. Building on structural simulations, we propose that melatonin may amplify Nimotuzumab's anti-glioma efficacy by inhibiting EGFR TK dimerization. This proposition was validated in our in vitro and in vivo studies where melatonin synergistically augmented cytotoxicity and apoptosis in Nimotuzumab-treated glioma cells. Thus, melatonin shows promise as a beneficial addition to Nimotuzumab treatment in glioma patients."}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0015"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "alt-text", "$": {"role": "short", "id": "alttext0010"}, "_": "Image 1"}, {"#name": "link", "$": {"xmlns:xlink": true, "locator": "ga1", "type": "simple", "role": "http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4", "href": "pii:S0304383524003136/ga1", "id": "aep-link-id7"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "author-highlights", "lang": "en", "id": "abs0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0020"}, "_": "Highlights"}, {"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "$$": [{"#name": "list", "$": {"id": "ulist0010"}, "$$": [{"#name": "list-item", "$": {"id": "u0010"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0010", "view": "all"}, "_": "The study investigates the significant link between circadian rhythms, melatonin, and brain tumors hinting at potential benefits of melatonin in advancing brain tumor treatments."}]}, {"#name": "list-item", "$": {"id": "u0015"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0015", "view": "all"}, "_": "A first-of-its-kind proteomic analysis of gliomas post-melatonin exposure was carried out, highlighting rapid shifts in glioma treatment methods and the discovery of potential disease markers."}]}, {"#name": "list-item", "$": {"id": "u0020"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0020", "view": "all"}, "_": "Through protein interaction models and 3D simulations, a mechanism of action for melatonin was found, delivering crucial understanding of glioma-related proteins."}]}]}]}]}]}]}}